389 related articles for article (PubMed ID: 31562607)
1. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
[TBL] [Abstract][Full Text] [Related]
2. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany.
Wilke T; Groth A; Long GH; Tatro AR; Sun D
Clin Ther; 2020 Jan; 42(1):130-143.e3. PubMed ID: 31883702
[TBL] [Abstract][Full Text] [Related]
3. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.
Park KT; Ehrlich OG; Allen JI; Meadows P; Szigethy EM; Henrichsen K; Kim SC; Lawton RC; Murphy SM; Regueiro M; Rubin DT; Engel-Nitz NM; Heller CA
Inflamm Bowel Dis; 2020 Jan; 26(1):1-10. PubMed ID: 31112238
[TBL] [Abstract][Full Text] [Related]
4. Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy.
Dovizio M; Hartz S; Buzzoni C; Redondo I; Nedeljkovic Protic M; Birra D; Perrone V; Veronesi C; Degli Esposti L; Armuzzi A
Adv Ther; 2024 Jun; 41(6):2282-2298. PubMed ID: 38619721
[TBL] [Abstract][Full Text] [Related]
5. Mental Health Costs of Inflammatory Bowel Diseases.
Szigethy E; Murphy SM; Ehrlich OG; Engel-Nitz NM; Heller CA; Henrichsen K; Lawton R; Meadows P; Allen JI
Inflamm Bowel Dis; 2021 Jan; 27(1):40-48. PubMed ID: 32095835
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
7. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
8. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
9. Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab
Ylisaukko-Oja T; Torvinen S; Ventola H; Schmidt S; Herrala S; Kononoff J; Voutilainen M
Scand J Gastroenterol; 2019 Jun; 54(6):726-732. PubMed ID: 31203693
[No Abstract] [Full Text] [Related]
10. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
Burisch J; Vardi H; Schwartz D; Friger M; Kiudelis G; Kupčinskas J; Fumery M; Gower-Rousseau C; Lakatos L; Lakatos PL; D'Incà R; Sartini A; Valpiani D; Giannotta M; Arebi N; Duricova D; Bortlik M; Chetcuti Zammit S; Ellul P; Pedersen N; Kjeldsen J; Midjord JMM; Nielsen KR; Winther Andersen K; Andersen V; Katsanos KH; Christodoulou DK; Domislovic V; Krznaric Z; Sebastian S; Oksanen P; Collin P; Barros L; Magro F; Salupere R; Kievit HAL; Goldis A; Kaimakliotis IP; Dahlerup JF; Eriksson C; Halfvarson J; Fernandez A; Hernandez V; Turcan S; Belousova E; Langholz E; Munkholm P; Odes S;
Lancet Gastroenterol Hepatol; 2020 May; 5(5):454-464. PubMed ID: 32061322
[TBL] [Abstract][Full Text] [Related]
11. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
12. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
13. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.
Kappelman MD; Rifas-Shiman SL; Porter CQ; Ollendorf DA; Sandler RS; Galanko JA; Finkelstein JA
Gastroenterology; 2008 Dec; 135(6):1907-13. PubMed ID: 18854185
[TBL] [Abstract][Full Text] [Related]
14. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry.
Bokemeyer B; Hardt J; Hüppe D; Prenzler A; Conrad S; Düffelmeyer M; Hartmann P; Hoffstadt M; Klugmann T; Schmidt C; Weismüller J; Mittendorf T; Raspe H
J Crohns Colitis; 2013 Jun; 7(5):355-68. PubMed ID: 22503168
[TBL] [Abstract][Full Text] [Related]
15. Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.
Schoepfer A; Vavricka SR; Brüngger B; Reich O; Blozik E; Bähler C
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):868-875. PubMed ID: 29757772
[TBL] [Abstract][Full Text] [Related]
16. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.
Rubin DT; Mody R; Davis KL; Wang CC
Aliment Pharmacol Ther; 2014 May; 39(10):1143-55. PubMed ID: 24697826
[TBL] [Abstract][Full Text] [Related]
17. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
[TBL] [Abstract][Full Text] [Related]
18. A Phenome-Wide Analysis of Healthcare Costs Associated with Inflammatory Bowel Diseases.
Cai W; Cagan A; He Z; Ananthakrishnan AN
Dig Dis Sci; 2021 Mar; 66(3):760-767. PubMed ID: 32436120
[TBL] [Abstract][Full Text] [Related]
19. Economic Burden and Health Care Access for Patients With Inflammatory Bowel Diseases in China: Web-Based Survey Study.
Yu Q; Zhu C; Feng S; Xu L; Hu S; Chen H; Chen H; Yao S; Wang X; Chen Y
J Med Internet Res; 2021 Jan; 23(1):e20629. PubMed ID: 33399540
[TBL] [Abstract][Full Text] [Related]
20. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital.
Bernstein CN; Papineau N; Zajaczkowski J; Rawsthorne P; Okrusko G; Blanchard JF
Am J Gastroenterol; 2000 Mar; 95(3):677-83. PubMed ID: 10710056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
